More than 90% of GIs are ‘somewhat comfortable’ prescribing adalimumab biosimilars

Most gastroenterologists reported higher familiarity with adalimumab biosimilars and reported greater comfort levels in prescribing biosimilars than dermatologists or rheumatologists, according to a recent survey.In its 2023 Biosimilars Report, Cardinal Health surveyed 350 providers in rheumatology, gastroenterology, dermatology and ophthalmology to assess market trends and changing perspectives toward biosimilars specifically. The survey found that 93% of GIs reported that they were “at least somewhat comfortable prescribing adalimumab biosimilars,” whereas only 86% ofRead More

Generated by Feedzy